CPTx, a biotechnology company developing in vivo genetic medicines built with programmable single-stranded DNA (ssDNA), announced the QUIET-CAR collaborative project with NanoCell Therapeutics has received a Eurostars Grant from the European Union through the Horizon Europe program and Eureka Network. The focus of the QUIET-CAR project is development of targeted lipid nanoparticles carrying novel immune-silent ssDNA for in vivo CAR T therapy.
"CPTx is committed to bringing in vivo CAR T therapies to patients through our proprietary pipeline development programs and now also through the QUIET-CAR project with NanoCell,” said Hendrik Dietz, CEO of CPTx. “The QUIET-CAR project represents another innovative approach to CAR T, and we look forward to advancing it together. Being selected from so many high-quality submissions underscores the promise of the project and the strength of our technology."
Eurostars, part of the European Partnership on Innovative SMEs and supported by Horizon Europe, is a funding initiative to accelerate transnational innovation. With participation from 37 countries, the program selects only the most promising technological breakthroughs, evaluated by independent experts. The selection of the CPTx – NanoCell project from more than 120 proposals reflects QUIET-CAR’s strong scientific and clinical potential across oncology and autoimmune diseases. NanoCell Therapeutics is a privately held biotechnology company pioneering transformative in vivo cell engineering through its non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!